A Phase II, Four-week, Multi-center, Double-blind, Placebo-controlled Parallel Group Study to Evaluate the Safety and Efficacy of EGT0001442 in Type 2 Diabetic Subjects.
Phase of Trial: Phase II
Latest Information Update: 06 Aug 2013
At a glance
- Drugs Bexagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 25 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Oct 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.